Effectiveness of a transdisciplinary approach on hyperphagia management among patients with Prader Willi syndrome

Butler, 2019, Prader–Willi syndrome – clinical genetics diagnosis and treatment approaches: an update, Curr Pediatr Rev, 15, 207, 10.2174/1573396315666190716120925 Khan, 2018, Mechanisms of obesity in Prader–Willi syndrome, Pediatr Obes, 13, 3, 10.1111/ijpo.12177 Díez, 2014, Prader–Willi syndrome and hyperphagia: a challenge to investigate, Endocrinol Nutr (English Ed), 3, 121, 10.1016/j.endonu.2014.02.001 Fuchs-Tarlovsky, 2012, Abnormalities in energy expenditure and respiratory parameters in patients with Prader Willi syndrome, Rev Chil Nutr, 39, 159, 10.4067/S0717-75182012000400008 Miller, 2011, Nutritional phases in Prader–Willi syndrome, Am J Med Genet A, 155, 1040, 10.1002/ajmg.a.33951 Duis, 2019, A multidisciplinary approach to the clinical management of Prader–Willi syndrome, Mol Genet Genomic Med, 7, e514, 10.1002/mgg3.514 Forster, 2005, 1 Tan, 2020, Current and emerging therapies for managing hyperphagia and obesity in Prader–Willi syndrome: a narrative review, Obes Rev, 21, e12992, 10.1111/obr.12992 Ho, 2010, Clinical management of behavioural characteristics of Prader–Willi syndrome, Neuropsychiatr Dis Treat, 6, 107 Heymsfield, 2014, Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia, Obesity (Silver Spring), 22, S1, 10.1002/oby.20646 Allas, 2018, AZP-531, an unacylated ghrelin analog, improves food-related behaviour in patients with Prader–Willi syndrome: a randomized placebo-controlled trial, PLOS ONE, 13, e0190849, 10.1371/journal.pone.0190849